Claimant Eligibility Sample Clauses

Claimant Eligibility. To be eligible to receive a settlement payment pursuant to the Settlement Agreement, a Settling Claimant must: (a) be, or if acting in a representative capacity, be representing the interest of a Canadian resident; and (b) provide Injury Evidence for at least one Eligible Injury; and (c) provide Prescription Evidence of `use of an Invokana Product at the time of, or prior to, such Eligible Injury; and (d) In the event that the Eligible Injury(s) occurred within 3 months after the addition of relevant warning language to a Dear Health Care Professional Letter or Product Monograph (for acute kidney injury claims, after January 25, 2016; for diabetic ketoacidosis claims, after May 31, 2016; and for limb loss claims, after September 6, 2017), provide evidence that the Settling Claimant (i) started using an Invokana Product at least 30 days before the date of the Eligible Injury and (ii) continuously used an Invokana Product from such date to the time of the Eligible Injury without having either attended his or her prescribing physician or had their prescription renewed otherwise. This evidence may be established by way of medical or pharmacy records, or by way of Declaration; and (e) properly complete, execute and submit a Claim Form to the Claims Administrator by the Claim Deadline.

Claimant Eligibility. To be eligible to receive a settlement payment pursuant to the Settlement Agreement, a claimant must: i. be, or if acting in a representative capacity, be representing the interest of a Canadian resident; and ii. demonstrate, from contemporaneous medical records, one of the following cardiac events: a. received a final diagnosis of a myocardial infarction (which includes a final diagnosis in medical records generated in the course of medical care that interpret clinical signs and/or diagnostic tests as establishing the occurrence of an MI at or about such time or, alternatively for purposes of this criterion, death from a cardiac event in the absence of any other cause of death); b. received a final diagnosis of initial onset or exacerbation of congestive heart failure (“CHF”) (which includes a final diagnosis in medical records generated in the course of medical care that interprets clinical signs and/or diagnostic tests as establishing the initial onset or exacerbation of CHF at or about such time); c. underwent a coronary artery bypass graft (CABG); or d. underwent a percutaneous coronary intervention with stent placement. iii. demonstrate, from contemporaneous medical or pharmacy records, at least 30 days of uninterrupted Avandia usage at the time of, or within one year prior to, such cardiac event; and iv. demonstrate, from contemporaneous medical or pharmacy records, that such Avandia use occurred prior to December 2010, or that an uninterrupted period of such use began prior to December 2010.

Claimant Eligibility